Key result
Apatinib in combination with chemotherapy showed a clinical response in a patient with relapsed and metastasized fibrosarcomatous dermatofibrosarcoma protuberans.
Why the study?
There were no reports evaluating the VEGFR-2 inhibitor apatinib as an antiangiogenesis therapy in metastatic fibrosarcomatous dermatofibrosarcoma protuberans.
Case Report (n=1)
Apatinib combined with chemotherapy may be a potential therapeutic option for metastatic fibrosarcomatous dermatofibrosarcoma protuberans.
Supports exploration of apatinib-chemotherapy in rare sarcomas; leaves open need for prospective validation before any practice change.
Dermatofibrosarcoma protuberans (DFSP) is soft tissue malignancy which is locally aggressive, slow-growth, rarely metastasizing but recurs frequently after surgical excision. Fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) is a variant of DFSP with a higher risk of recurrence and metastasis. For treatment of metastatic DFSP, antiangiogenesis therapy is an important therapeutic option, which is beneficial in increasing the efficacy of chemotherapy. Apatinib is a novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor and revealed potential anti-tumor efficacy in some types of sarcomas. However, there is still no report of apatinib as an angiogenesis therapy for metastatic DFSP to date. Herein we first describe a case of FS-DFSP relapsed and metastasized post multiple surgeries and adjuvant radiotherapy responded to apatinib in combination with chemotherapy, indicating apatinib may be a potential therapeutic option for metastatic DFSP.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a case report in Fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) with pulmonary metastases (n=1). Apatinib in combination with chemotherapy was evaluated on Response to treatment. Apatinib in combination with chemotherapy showed a clinical response in a patient with relapsed and metastasized fibrosarcomatous dermatofibrosarcoma protuberans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: